William Blair & Company
NERV icon

William Blair & Company’s Minerva Neurosciences NERV Stock Holding History

William Blair & Company’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3,138
Closed -$151K – 1720
2020
Q1 		$151K Hold
3,138
– – ﹤0.01% 1235
2019
Q4 		$178K Buy
3,138
+194
+7% +$8.55K ﹤0.01% 1333
2019
Q3 		$183K Buy
2,944
+1,575
+115% +$89.2K ﹤0.01% 1287
2019
Q2 		$62K Hold
1,369
– – ﹤0.01% 1472
2019
Q1 		$86K Buy
+1,369
New +$82.3K ﹤0.01% 1419
2017
Q4 		– Sell
-1,250
Closed -$76K – 1419
2017
Q3 		$76K Hold
1,250
– – ﹤0.01% 1317
2017
Q2 		$89K Hold
1,250
– – ﹤0.01% 1433
2017
Q1 		$88K Hold
1,250
– – ﹤0.01% 1297
2016
Q4 		$118K Hold
1,250
– – ﹤0.01% 1205
2016
Q3 		$141K Buy
+1,250
New +$121K ﹤0.01% 1210

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

William Blair & Company's NERV Position: Q2 2020 in Review

William Blair & Company sold out of Minerva Neurosciences (NERV) in Q2 2020, closing a stake of 3,138 shares — an estimated $151K sold.

William Blair & Company first reported a position in NERV in Q3 2016 and held it in 10 quarters. The position peaked at $183K in Q3 2019. 80 funds tracked by Wall St. Rank hold NERV as of Q2 2020.

  • William Blair & Company reported no remaining Minerva Neurosciences position as of Q2 2020 after selling out during the quarter.
  • William Blair & Company sold 3,138 Minerva Neurosciences shares in Q2 2020, an estimated $151K.
  • William Blair & Company first reported a position in Minerva Neurosciences in Q3 2016 and held it in 10 quarters.
  • William Blair & Company's Minerva Neurosciences position peaked at $183K in Q3 2019.
  • 80 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2020.

Based on William Blair & Company's 13F filing for Q2 2020, filed 12 Aug 2020.